Azacitidine Tablet 200 mg, 300 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 200 mg, 300 mg

Reference Brands: Onureg (USA)

Category: Oncology Cancer Care

Azacitidine is used in the treatment of some kinds of blood cancer. It is used for the treatment of adult patients with all subtypes of Myelodysplastic Syndrome (MDS). It may be also used to treat other conditions, as determined by the doctor.

Product Description:

Azacitidine, marketed under the brand name Vidaza among others, is a chemotherapeutic agent used primarily in the treatment of myelodysplastic syndromes (MDS), myeloid leukemia, and juvenile myelomonocytic leukemia. As a chemical analog of cytidine, a nucleoside found in DNA and RNA, azacitidine integrates into nucleic acids and exerts its therapeutic effects by interfering with abnormal DNA methylation, ultimately promoting the reactivation of silenced genes that regulate normal cell growth and differentiation.

First synthesized in Czechoslovakia alongside its deoxy derivative, decitabine, azacitidine was developed as a potential cancer therapy. It received approval from the U.S. Food and Drug Administration (FDA) on May 19, 2004, for the treatment of myelodysplastic syndromes. Clinical studies have demonstrated its efficacy in normalizing blood cell counts and bone marrow morphology, with a significant proportion of patients experiencing reduced dependence on blood transfusions. Azacitidine represents a key therapeutic option for managing hematologic malignancies, offering improved hematologic function and quality of life for patients with MDS and related disorders.